Burden of Hospitalized Viral Respiratory Infections in France: Insights From the 2022-2023 Season
Author(s)
Nicolas Capit, PhD1, Liem Binh Luong, MD2, Laureen Majed, PhD1, Aleksandra Anchim, PhD1, Ellina Degand, PharmD1, Cécile Artaud, MSc1, Clélia Bignon-Favary, MSc3, Sophie LARRIEU, PhD3, Claire Marant Micallef, PharmD4, Yvanie Caillé, MSc5, Marie Lachâtre, MD2, Slim Fourati, MD6.
1AstraZeneca, Courbevoie, France, 2Centre d'investigation clinique de vaccinologie, AP-HP Hôpital Cochin, Paris, France, 3HORIANA, BORDEAUX, France, 4PELyon, Lyon, France, 5Renaloo, Paris, France, 6Department of Virology, AP-HP Hôpitaux Universitaires Henri Mondor, Créteil, France.
1AstraZeneca, Courbevoie, France, 2Centre d'investigation clinique de vaccinologie, AP-HP Hôpital Cochin, Paris, France, 3HORIANA, BORDEAUX, France, 4PELyon, Lyon, France, 5Renaloo, Paris, France, 6Department of Virology, AP-HP Hôpitaux Universitaires Henri Mondor, Créteil, France.
OBJECTIVES: Viral respiratory infections impose a substantial burden on healthcare systems, with immunocompromised (IC) individuals particularly susceptible to adverse outcomes. This study aims to quantify the clinical and economic burden of viral respiratory infections (COVID-19, Influenza, respiratory syncytial virus (RSV)) among IC and non-IC patients in France from July 2022 to June 2023, utilizing data from the national hospital claims database (Programme de Médicalisation des Systèmes d'Information).
METHODS: A retrospective analysis was conducted on patients aged 2 and above, hospitalized between July 1, 2022, and June 30, 2023, due to COVID-19, influenza, or RSV. IC status was defined as presence of primary immunodeficiency, malignant hemopathies, end-stage renal disease, active solid tumor therapy, hematopoietic stem cell or solid organ transplantation, identified through medical codes. Outcomes included hospitalizations, length of stay, ICU admissions, in-hospital mortality, and costs (including rehospitalizations for the pathogen).
RESULTS: During the study period, 170,512 patients were hospitalized for viral respiratory infection; 16,809 (9.9%) were IC. The total cost was €965.9 million, with €133.5 million (13.8%) attributable to IC patients. Hospitalizations included 102,943 for COVID-19 (11,115 [10.8%] IC), 51,573 for influenza (3,965 [7.7%] IC), and 19,653 for RSV (2,369 [12.1%] IC). Among non-IC individuals, median length of stay ranged from 4.0 days (influenza) to 6.0 days (COVID-19/RSV), ICU admission rates [8.4% (COVID-19), 14.0% (RSV)], and in-hospital mortality rates [4.5% (influenza), 8.8% (COVID-19)]. IC patients experienced longer stays [6.0 days (influenza), 7.0 days (COVID-19/RSV)], higher ICU admissions [15.6% (COVID-19), 19.3% (RSV)], and greater mortality [8.1% (RSV), 11.6% (COVID-19)].
CONCLUSIONS: Hospitalized viral respiratory infections imposed nearly €1 billion burden on the French healthcare. Despite accounting for around 0.5% of the French population, IC patients accounted for 9.9% of hospitalizations and 13.8% of associated costs. These figures likely underestimate the true burden due to reliance on testing, coding, and under-capture of sequelae such as comorbidity decompensations.
METHODS: A retrospective analysis was conducted on patients aged 2 and above, hospitalized between July 1, 2022, and June 30, 2023, due to COVID-19, influenza, or RSV. IC status was defined as presence of primary immunodeficiency, malignant hemopathies, end-stage renal disease, active solid tumor therapy, hematopoietic stem cell or solid organ transplantation, identified through medical codes. Outcomes included hospitalizations, length of stay, ICU admissions, in-hospital mortality, and costs (including rehospitalizations for the pathogen).
RESULTS: During the study period, 170,512 patients were hospitalized for viral respiratory infection; 16,809 (9.9%) were IC. The total cost was €965.9 million, with €133.5 million (13.8%) attributable to IC patients. Hospitalizations included 102,943 for COVID-19 (11,115 [10.8%] IC), 51,573 for influenza (3,965 [7.7%] IC), and 19,653 for RSV (2,369 [12.1%] IC). Among non-IC individuals, median length of stay ranged from 4.0 days (influenza) to 6.0 days (COVID-19/RSV), ICU admission rates [8.4% (COVID-19), 14.0% (RSV)], and in-hospital mortality rates [4.5% (influenza), 8.8% (COVID-19)]. IC patients experienced longer stays [6.0 days (influenza), 7.0 days (COVID-19/RSV)], higher ICU admissions [15.6% (COVID-19), 19.3% (RSV)], and greater mortality [8.1% (RSV), 11.6% (COVID-19)].
CONCLUSIONS: Hospitalized viral respiratory infections imposed nearly €1 billion burden on the French healthcare. Despite accounting for around 0.5% of the French population, IC patients accounted for 9.9% of hospitalizations and 13.8% of associated costs. These figures likely underestimate the true burden due to reliance on testing, coding, and under-capture of sequelae such as comorbidity decompensations.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH34
Topic
Clinical Outcomes, Epidemiology & Public Health, Real World Data & Information Systems
Disease
Infectious Disease (non-vaccine)